TECX
+$0
76,500 sh
REICIN ALISE
Director, Chief Executive Officer, PRES., GLOBAL CLINICAL DEV. · SEC CIK 1757533Advertisement
Buy track record
How this insider's open-market purchases have performed100%
of buys now in profit
1 up · 0 down
Avg return since buy+33.3%
Median return+33.3%
Best trade+33.3%
Worst trade+33.3%
Buys scored1
Average return by holding period — separates good entry timing from riding one long winner
After 1 month
+58.1%
100% won · 1 trade
After 3 months
+25.0%
100% won · 1 trade
After 6 months
—
not elapsed yet
After 12 months
—
not elapsed yet
| Date | Company | 90d trend | Buy price | Value | ΔOwn | 1M | 3M | 6M | 12M | To date |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 11, 2026 | TECX | $21 | $52.8K | +1.1% | +58.1% | +25.0% | — | — | +33.3% |
How this is calculated. We score only open-market purchases (SEC code
P) — the buys that carry real signal. Each trade's return is measured from the adjusted closing price on the purchase date to the latest close, accounting for stock splits and dividends. The 1M/3M/6M/12M columns show the same trade's return after each fixed holding period; a dash means that horizon hasn't elapsed yet or isn't priceable. Sales are excluded because insiders sell for many routine reasons. With only 1 scored trade, treat this as a small sample, not a verdict.
Advertisement
Open-market buys
$52.8K
1 trades
Open-market sells
$0
0 trades
Net flow
+$52.8K
Net buying
Total filings
16
transactions shown
Full transaction history
All Form 4 activity across every company, newest firstTECX
Reicin Alise, TECX's CEO, spent $52.8K of their own money on 2,500 shares at $21, growing their stake 1%.
+$52.8K
2,500 sh @ $21
TECX
−$95.3K
4,104 sh @ $23
TECX
+$26.1K
10,966 sh @ $2
TECX
+$0
14,700 sh
Advertisement
TECX
−$17K
859 sh @ $20
TECX
+$0
36,047 sh
TECX
+$0
11,717 sh
TECX
+$0
166,580 sh
TECX
+$0
124,530 sh
CELG
+$0
4,298 sh
CELG
+$0
8,927 sh
CELG
+$0
24,209 sh
CELG
−$0
44,615 sh
CELG
+$0
11,903 sh
CELG
−$512.5K
4,722 sh @ $109
Frequently asked questions
How is REICIN ALISE's win rate calculated?
We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.
Why are some buys not included in the score?
A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.
What do the 1M / 3M / 6M / 12M columns mean?
They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.
Does a high win rate mean I should copy this insider?
No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.
Where does this data come from?
Trades come from REICIN ALISE's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.